drugset / Trial / NCT06596473
A Study of BG-C477 in Participants With Advanced Solid Tumors
Non-randomizedSequentialOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of BG-C477 alone and in combination with anticancer agents in participants with selected advanced solid tumors.
Timeline
- Start
- 2024-10-03
- Primary completion
- 2027-12-31
- Completion
- 2027-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BG-C477 | Unknown | — | Intravenous |
| Background | Tislelizumab | Monoclonal antibody | — | Intravenous |